hesperidin, diosmin | Venarus tablets are coated. 1000 mg 60 pcs.
Special Price
$44.62
Regular Price
$54.00
In stock
SKU
BID823817
Release form
Tablets, film-coated, orange-pink, biconvex, oblong with rounded ends, with a risk.
On a cross-section, the nucleus is grayish yellow to brownish gray.
Tablets, film-coated, orange-pink, biconvex, oblong with rounded ends, with a risk.
On a cross-section, the nucleus is grayish yellow to brownish gray.
Release form
Tablets, film-coated, orange-pink, biconvex, oblong with rounded ends, with a risk.
On a cross-section, the nucleus is grayish yellow to brownish gray.
Packing
Film-coated tablets, 1000 mg.
In a package of 60 pcs., which, together with instructions for use, are placed in a pack of cardboard.
Pharmacological action
Venarus® has an angioprotective and venotonic effect.
Reduces the extensibility of veins, increases their tone and reduces venous congestion, reduces permeability, fragility of capillaries and increases their resistance improves microcirculation and lymphatic drainage.
With systematic use, reduces the severity of the clinical manifestations of chronic venous insufficiency of the lower extremities of an organic and functional nature.
The optimal dose-response ratio is observed with 1000 mg per day.
Indications
Venarus® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).
Therapy for symptoms of venous-lymphatic insufficiency:
cramps of the lower extremities
feeling of heaviness and fullness in the legs
pain
"tired" legs.
Therapy for manifestations of venous-lymphatic insufficiency:
edema of the lower extremities
trophic changes in the skin and subcutaneous tissue
venous trophic ulcers.
Symptomatic therapy of acute and chronic hemorrhoids.
Contraindications
Hypersensitivity to the active components or excipients that make up the drug.
Not recommended for women during breastfeeding.
Pregnancy and lactation
Pregnancy:
Animal experiments have not revealed teratogenic effects. To date, there have been no reports of any side effects when using the drug in pregnant women.
Breastfeeding period:
Due to the lack of data on the excretion of the drug with breast milk, it is not recommended to take the drug for women during breastfeeding.
Reproductive effects:
Reproductive toxicity studies have not shown an effect on reproductive function in rats of either sex.
Special instructions
Before you start taking the drug VenarusВ®, it is recommended to consult a doctor.
With exacerbation of hemorrhoids, the administration of VenarusВ® does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the time specified in the section "Method of application and dose." In the event that the symptoms do not disappear after the recommended course of therapy, an examination by a proctologist should be performed, who will select further therapy.
In the presence of impaired venous circulation, the maximum treatment effect is ensured by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, prolonged stay on the legs, and it is recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings helps to improve blood circulation.
Impact on the ability to drive vehicles and mechanisms: not affected.
Seek medical attention immediately if your condition worsens during treatment or if there is no improvement.
Composition
1 tablet contains:
active ingredients: hesperidin (in terms of 100% substance) 100 mg,
diosmin (in terms of 100% substance) 900 mg
excipients: microcrystalline cellulose 124 mg,
sodium carboxymethyl starch (sodium starch glycolate) 54 mg,
gelatin 62 mg,
talcum 12 mg,
magnesium stearate 8 mg
coating aids:
hypromellose 41 mg polyglycol (hydroxyglycol) 6000) 6.76 mg, sodium lauryl sulfate 0.2 mg, magnesium stearate 2.48 mg, titanium dioxide 7.88 mg, iron oxide red 0.6 mg, iron oxide yellow 0.68 mg.
Dosage and Administration
Inside.
The recommended dose for venous-lymphatic insufficiency is 1 tablet per day, preferably in the morning, during meals. The risk on the tablet is intended solely for division in order to facilitate swallowing.
The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.
The recommended dose for acute hemorrhoids is 3 tablets per day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets per day (1 tablet in the morning and evening) for the next 3 days.
The recommended dose for chronic hemorrhoids is 1 tablet per day.
Active ingredient
frefd310, frequent reactions: often (? 1/100 and <1/10 cases), infrequently (? 1/1000 and < 1/100 cases), rarely (? 1/10000 and <1/1000 cases) and very rarely (<1/10000 cases). Unwanted reactions, the frequency of development of which cannot be estimated from the available data, are referred to as “frequency unknown”.
From the central nervous system: rarely - dizziness, headache, general malaise.
From the gastrointestinal tract: often - diarrhea, dyspepsia, nausea, vomiting infrequently - incidence of unknown colitis - abdominal pain.
From the skin: rarely - rash, itching, urticaria, frequency is unknown - isolated swelling of the face, lips, eyelids, in exceptional cases, angioedema.
If any of the adverse reactions listed in the instructions are exacerbated, or if you notice other adverse reactions not listed in the instructions, notify your doctor.
Drug Interactions
Not observed. The attending physician should be informed of all medications taken.
Overdose
Overdose has not been reported.
If you overdose, seek medical advice immediately.
Shelf life
3 years. Do not use after the expiration date indicated on the package.
Terms and conditions
without prescription
dosage form
tablets
Prescription
Prescription
Pregnant as prescribed by the doctor, Adults prescribed by a doctor
Tablets, film-coated, orange-pink, biconvex, oblong with rounded ends, with a risk.
On a cross-section, the nucleus is grayish yellow to brownish gray.
Packing
Film-coated tablets, 1000 mg.
In a package of 60 pcs., which, together with instructions for use, are placed in a pack of cardboard.
Pharmacological action
Venarus® has an angioprotective and venotonic effect.
Reduces the extensibility of veins, increases their tone and reduces venous congestion, reduces permeability, fragility of capillaries and increases their resistance improves microcirculation and lymphatic drainage.
With systematic use, reduces the severity of the clinical manifestations of chronic venous insufficiency of the lower extremities of an organic and functional nature.
The optimal dose-response ratio is observed with 1000 mg per day.
Indications
Venarus® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).
Therapy for symptoms of venous-lymphatic insufficiency:
cramps of the lower extremities
feeling of heaviness and fullness in the legs
pain
"tired" legs.
Therapy for manifestations of venous-lymphatic insufficiency:
edema of the lower extremities
trophic changes in the skin and subcutaneous tissue
venous trophic ulcers.
Symptomatic therapy of acute and chronic hemorrhoids.
Contraindications
Hypersensitivity to the active components or excipients that make up the drug.
Not recommended for women during breastfeeding.
Pregnancy and lactation
Pregnancy:
Animal experiments have not revealed teratogenic effects. To date, there have been no reports of any side effects when using the drug in pregnant women.
Breastfeeding period:
Due to the lack of data on the excretion of the drug with breast milk, it is not recommended to take the drug for women during breastfeeding.
Reproductive effects:
Reproductive toxicity studies have not shown an effect on reproductive function in rats of either sex.
Special instructions
Before you start taking the drug VenarusВ®, it is recommended to consult a doctor.
With exacerbation of hemorrhoids, the administration of VenarusВ® does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the time specified in the section "Method of application and dose." In the event that the symptoms do not disappear after the recommended course of therapy, an examination by a proctologist should be performed, who will select further therapy.
In the presence of impaired venous circulation, the maximum treatment effect is ensured by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, prolonged stay on the legs, and it is recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings helps to improve blood circulation.
Impact on the ability to drive vehicles and mechanisms: not affected.
Seek medical attention immediately if your condition worsens during treatment or if there is no improvement.
Composition
1 tablet contains:
active ingredients: hesperidin (in terms of 100% substance) 100 mg,
diosmin (in terms of 100% substance) 900 mg
excipients: microcrystalline cellulose 124 mg,
sodium carboxymethyl starch (sodium starch glycolate) 54 mg,
gelatin 62 mg,
talcum 12 mg,
magnesium stearate 8 mg
coating aids:
hypromellose 41 mg polyglycol (hydroxyglycol) 6000) 6.76 mg, sodium lauryl sulfate 0.2 mg, magnesium stearate 2.48 mg, titanium dioxide 7.88 mg, iron oxide red 0.6 mg, iron oxide yellow 0.68 mg.
Dosage and Administration
Inside.
The recommended dose for venous-lymphatic insufficiency is 1 tablet per day, preferably in the morning, during meals. The risk on the tablet is intended solely for division in order to facilitate swallowing.
The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.
The recommended dose for acute hemorrhoids is 3 tablets per day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets per day (1 tablet in the morning and evening) for the next 3 days.
The recommended dose for chronic hemorrhoids is 1 tablet per day.
Active ingredient
frefd310, frequent reactions: often (? 1/100 and <1/10 cases), infrequently (? 1/1000 and < 1/100 cases), rarely (? 1/10000 and <1/1000 cases) and very rarely (<1/10000 cases). Unwanted reactions, the frequency of development of which cannot be estimated from the available data, are referred to as “frequency unknown”.
From the central nervous system: rarely - dizziness, headache, general malaise.
From the gastrointestinal tract: often - diarrhea, dyspepsia, nausea, vomiting infrequently - incidence of unknown colitis - abdominal pain.
From the skin: rarely - rash, itching, urticaria, frequency is unknown - isolated swelling of the face, lips, eyelids, in exceptional cases, angioedema.
If any of the adverse reactions listed in the instructions are exacerbated, or if you notice other adverse reactions not listed in the instructions, notify your doctor.
Drug Interactions
Not observed. The attending physician should be informed of all medications taken.
Overdose
Overdose has not been reported.
If you overdose, seek medical advice immediately.
Shelf life
3 years. Do not use after the expiration date indicated on the package.
Terms and conditions
without prescription
dosage form
tablets
Prescription
Prescription
Pregnant as prescribed by the doctor, Adults prescribed by a doctor
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review